Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Vav1, a GDP/GTP nucleotide exchange factor (GEF), is implicated in human cancers, including lung cancer, due to mutations or overexpression.
• Vav1 is typically restricted to the hematopoietic system and its activity is regulated by tyrosine phosphorylation.

Purpose of the Study:

• To investigate the in-vivo role of Vav1 in lung cancer development.
• To determine if Vav1 cooperates with oncogenes like mutant K-Ras in lung tumorigenesis.

Main Methods:

• Generation of novel transgenic mouse strains expressing Vav1, K-RasG12D, or both in type II pneumocytes.
• Analysis of lung tumor development, immune cell infiltration, ERK phosphorylation, and cytokine levels.

Main Results:

• Coexpression of Vav1 and K-RasG12D significantly accelerated malignant lung cancer progression compared to K-RasG12D alone.
• Vav1 expression alone did not induce lung tumorigenesis.
• Increased B-cell, T-cell, and monocyte infiltration, elevated ERK phosphorylation, and increased IL-4/IL-13 levels were observed in K-RasG12D/Vav1 mice.

Conclusions:

• Vav1 and K-Ras synergize to promote lung tumor development.
• Vav1 contributes to lung cancer progression through its signaling pathways.
• The tumor microenvironment and immune responses are modulated by the coexpression of these oncogenes.